Story perspectives

Insurance denials force PMOS patient off semaglutide after 10 months

8/16/2026

Summary

Charlotte Stops GLP-1

Charlotte Touzalin, 18, finished a 10-month semaglutide trial for polyendocrine metabolic ovarian syndrome, shedding 42 pounds and normalizing her menstrual cycles.
Dr. Melanie Cree reported that GLP-1 drugs produced greater weight loss and a 52 % testosterone drop, with eight of 11 participants losing at least 10 % of body weight.
Insurance companies deny coverage for GLP-1 drugs because they lack PMOS or weight-loss approval, forcing Touzalin to stop the medication in June.

Summary

Experts Demand Inclusion

Dr. Jan Goral says the disorder formerly called polycystic ovarian syndrome, now PMOS, underscores its impact and need for coordinated care.
PMOS affects about one in eight women, roughly four million in the UK.
Experts say PMOS also occurs in transgender men, non-binary and gender-diverse people, urging inclusive criteria.
A story on the IVF Australia F Chat Podcast sparked discussion, prompting campaigns and explainer films to raise awareness of PMOS’s effects.

1 of 2

Charlotte Stops GLP-1

Charlotte Touzalin, 18, finished a 10-month semaglutide trial for polyendocrine metabolic ovarian syndrome, shedding 42 pounds and normalizing her menstrual cycles.
Dr. Melanie Cree reported that GLP-1 drugs produced greater weight loss and a 52 % testosterone drop, with eight of 11 participants losing at least 10 % of body weight.
Insurance companies deny coverage for GLP-1 drugs because they lack PMOS or weight-loss approval, forcing Touzalin to stop the medication in June.

1 / 2